Minimal residual disease assessment in multiple myeloma by
multiparametric flow cytometry

J 2017

Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry

RIHOVA, L., Pavla VŠIANSKÁ, Renata BEZDĚKOVÁ, Romana KRÁLOVÁ, Miroslav PENKA et. al.

Základní údaje

Originální název

Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry

Název česky

Analýza minimální reziduální nemoci u mnohočetného myelomu pomocí multiparametrické průtokové cytometrie

Autoři

RIHOVA, L. (203 Česká republika, garant), Pavla VŠIANSKÁ (203 Česká republika), Renata BEZDĚKOVÁ (203 Česká republika), Romana KRÁLOVÁ (203 Česká republika), Miroslav PENKA (203 Česká republika), Marta KREJČÍ (203 Česká republika, domácí), Luděk POUR (203 Česká republika, domácí) a R. HAJEK (203 Česká republika)

Vydání

Klinická onkologie, Praha, Ambit Media, 2017, 0862-495X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/17:00097851

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.14735/amko20172S21

Klíčová slova anglicky

flow cytometry; minimal residual disease; multiple myeloma; plasma cells

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 3. 2018 17:39, Soňa Böhmová

Anotace

V originále

Background: Progress in treatment of multiple myeloma extensively increased patient remission rates, so minimal residual disease (MRD) detection becomes essential to assess the effectivity of treatment and depth of complete response. Nowadays, multiparametric flow cytometry(MFC) is the most used method for monitoring of MRD presence in the bone marrow of multiple myeloma patients; however, detection on molecular level can be used as well. It is evident that choice of protocol used for MFC-MRD assessment can significantly affect required results;nevertheless, standardized and highly sensitive approach of "next generation flow" is already available. Although benefit of MRD assessment as an independent predictor of progression- -free survival and over all survival is known, very recent research showed that MRD-negative status surpasses the prognostic value of complete response achievement for progression-free survival and over all survival. Aim: This review is focused on use MFC in MRD assessment in multiple myeloma. The technical aspects and clinical benefits of this approach are mentioned as well. Conclusion: The information about MRD level detected by highly sensitive and reproducible MFC can be potentially used as a bio marker to evaluate the efficacy of different treatment strategies, help on treatment decisions and act as a surrogate for over all survival in multiple myeloma patients.

Citovat

RIHOVA, L., Pavla VŠIANSKÁ, Renata BEZDĚKOVÁ, Romana KRÁLOVÁ, Miroslav PENKA, Marta KREJČÍ, Luděk POUR a R. HAJEK. Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry. Klinická onkologie. Praha: Ambit Media, 2017, roč. 30, Suppl. 2, s. "2S21"-"2S28", 8 s. ISSN 0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S21.

@article{1392118,
   author = {Rihova, L. and Všianská, Pavla and Bezděková, Renata and Králová, Romana and Penka, Miroslav and Krejčí, Marta and Pour, Luděk and Hajek, R.},
   article_location = {Praha},
   article_number = {Suppl. 2},
   doi = {http://dx.doi.org/10.14735/amko20172S21},
   keywords = {flow cytometry; minimal residual disease; multiple myeloma; plasma cells},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinická onkologie},
   title = {Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry},
   volume = {30},
   year = {2017}
}

TY  - JOUR
ID  - 1392118
AU  - Rihova, L. - Všianská, Pavla - Bezděková, Renata - Králová, Romana - Penka, Miroslav - Krejčí, Marta - Pour, Luděk - Hajek, R.
PY  - 2017
TI  - Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry
JF  - Klinická onkologie
VL  - 30
IS  - Suppl. 2
SP  - "2S21"-"2S28"
EP  - "2S21"-"2S28"
PB  - Ambit Media
SN  - 0862495X
KW  - flow cytometry
KW  - minimal residual disease
KW  - multiple myeloma
KW  - plasma cells
N2  - Background: Progress in treatment of multiple myeloma extensively increased patient remission rates, so minimal residual disease (MRD) detection becomes essential to assess the effectivity of treatment and depth of complete response. Nowadays, multiparametric flow cytometry(MFC) is the most used method for monitoring of MRD presence in the bone marrow of multiple myeloma patients; however, detection on molecular level can be used as well. It is evident that choice of protocol used for MFC-MRD assessment can significantly affect required results;nevertheless, standardized and highly sensitive approach of "next generation flow" is already available. Although benefit of MRD assessment as an independent predictor of progression- -free survival and over all survival is known, very recent research showed that MRD-negative status surpasses the prognostic value of complete response achievement for progression-free survival and over all survival. Aim: This review is focused on use MFC in MRD assessment in multiple myeloma. The technical aspects and clinical benefits of this approach are mentioned as well. Conclusion: The information about MRD level detected by highly sensitive and reproducible MFC can be potentially used as a bio marker to evaluate the efficacy of different treatment strategies, help on treatment decisions and act as a surrogate for over all survival in multiple myeloma patients.
ER  -

RIHOVA, L., Pavla VŠIANSKÁ, Renata BEZDĚKOVÁ, Romana KRÁLOVÁ, Miroslav PENKA, Marta KREJČÍ, Luděk POUR a R. HAJEK. Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry. \textit{Klinická onkologie}. Praha: Ambit Media, 2017, roč.~30, Suppl. 2, s.~''2S21''-''2S28'', 8 s. ISSN~0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko20172S21.

Podrobný výpis o publikaci